Technical Analysis for MLTX - MoonLake Immunotherapeutics
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | -0.20% | |
| Bollinger Band Squeeze | Range Contraction | -0.20% | |
| 20 DMA Resistance | Bearish | -2.45% | |
| Slingshot Bearish | Bearish Swing Setup | -2.45% | |
| Bollinger Band Squeeze | Range Contraction | -2.45% | |
| Hammer Candlestick | Bullish | -0.56% | |
| Bollinger Band Squeeze | Range Contraction | -0.56% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Gap Up Partially Closed | about 22 hours ago |
| Gapped Up (Partial) | about 22 hours ago |
| Up 3% | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/05/2024
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.98 |
| 52 Week Low | 24.31 |
| Average Volume | 412,963 |
| 200-Day Moving Average | 51.90 |
| 50-Day Moving Average | 45.22 |
| 20-Day Moving Average | 42.31 |
| 10-Day Moving Average | 42.47 |
| Average True Range | 2.07 |
| RSI (14) | 38.65 |
| ADX | 22.24 |
| +DI | 14.44 |
| -DI | 28.81 |
| Chandelier Exit (Long, 3 ATRs) | 39.36 |
| Chandelier Exit (Short, 3 ATRs) | 44.03 |
| Upper Bollinger Bands | 44.68 |
| Lower Bollinger Band | 39.93 |
| Percent B (%b) | 0.16 |
| BandWidth | 11.21 |
| MACD Line | -1.22 |
| MACD Signal Line | -1.22 |
| MACD Histogram | 0.008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 43.20 | ||||
| Resistance 3 (R3) | 43.46 | 42.88 | 42.78 | ||
| Resistance 2 (R2) | 42.88 | 42.25 | 42.75 | 42.64 | |
| Resistance 1 (R1) | 41.79 | 41.85 | 41.50 | 41.53 | 42.50 |
| Pivot Point | 41.21 | 41.21 | 41.07 | 41.08 | 41.21 |
| Support 1 (S1) | 40.12 | 40.58 | 39.83 | 39.86 | 38.88 |
| Support 2 (S2) | 39.54 | 40.18 | 39.41 | 38.74 | |
| Support 3 (S3) | 38.45 | 39.54 | 38.60 | ||
| Support 4 (S4) | 38.19 |
